Statement issued by the company (Announcement)<\/p>\n
April 22, 2026<\/p>\n
Clearances for Rembra CT, Rembra RT, and Areta RT enable high-throughput imaging at scale and elevate precision across the cancer care pathway<\/i><\/p>\n
Royal Philips<\/strong><\/a> (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA)<\/strong> for its Rembra platform of scanning systems, including Rembra CT<\/a>, <\/strong>Rembra RT and Areta RT<\/strong>.<\/a><\/p>\n The newly cleared systems are designed to help healthcare providers respond to growing demand for imaging and radiation therapy planning by helping to improve speed, efficiency, and access to high-quality imaging. As imaging volumes and clinical complexity continue to rise, healthcare providers need solutions that can help them work more efficiently while maintaining confidence in clinical decisions.<\/p>\n The Rembra platform of systems also extends the role of CT across both diagnostic radiology and radiation therapy, helping to enable more connected workflows and a coordinated approach to patient care\u2014from rapid assessment in acute settings to precise cancer treatment planning.<\/p>\n \u201cAs healthcare systems manage increasing demand and complexity, imaging plays a critical role in enabling timely and informed clinical decisions,\u201d said Dan Xu<\/strong>, Business Leader of CT at Philips. \u201cWith the Rembra platform, we are redefining what clinicians can expect from CT, combining speed, scalability, and precision to expand access to high-quality imaging while supporting confident diagnosis and highly accurate treatment planning.\u201d<\/p>\n With the largest-in-class 85 cm bore, Rembra CT is purpose-built for the front lines of care, enabling ultra-fast, high-throughput imaging in demanding clinical environments, supporting up to 270 exams per day [1] in various settings including emergency departments, critical care, and interventional settings. Its advanced acquisition and reconstruction capabilities support rapid, high-quality imaging at scale, helping clinicians make timely decisions in critical situations without compromising diagnostic confidence.<\/p>\n Rembra RT and Areta RT bring these performance advantages into radiation therapy, where precision is critical. These systems support high-fidelity imaging for treatment planning with a wide 85 cm extended field of view [2] and next generation 4DCT imaging capabilities, supporting more accurate targeting of tumors while helping protect healthy tissue. By streamlining simulation and planning workflows, they help reduce variability and improve efficiency, supporting more precise, personalized cancer care.<\/p>\n Together, the Rembra platform delivers a unified, high-performance CT ecosystem that spans the full care continuum\u2014from urgent diagnosis to precision-guided therapy. It empowers healthcare providers to manage increasing demand with greater speed, consistency, and confidence while enabling more connected and efficient care delivery.<\/p>\n The FDA clearances further strengthen Philips\u2019 comprehensive CT portfolio and reflect its continued focus on integrating advanced imaging technologies with intelligent and connected workflows. They also reflect Philips\u2019 ongoing commitment to evolving its CT offering to address the changing needs of today\u2019s imaging environments. By bringing together diagnostic and therapy solutions, Philips aims to support more efficient, coordinated care and improve the experience for both patients and care teams.<\/p>\n [1] Based on a sixteen-hour day, with throughput testing with 203 patient scans\/ 12 hours for Rembra with typical radiological profiles and protocols. Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people\u2019s health and well-being through meaningful innovation. Philips\u2019 patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.<\/p>\n Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com\/newscenter<\/a>.<\/p>\n AGENCIA EFE S.A.U.,S.M.E. shall not be liable for any information contained in this message and assumes no responsibility towards third parties in relation to its contents, being expressly exempt from any liability that the author may have in relation to the information in question. Agencia EFE reserves the right to distribute the press release on the news wire, or to publish it on EFE Comunica.<\/em><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":" Statement issued by the company (Announcement) April 22, 2026 Clearances for Rembra CT, Rembra RT, and Areta RT enable high-throughput imaging at scale and elevate precision across the cancer care […]<\/p>\n","protected":false},"author":198164071,"featured_media":48434,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[125518],"tags":[],"class_list":["post-220629","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire-en"],"acf":[],"yoast_head":"\n
\n[2] The Extended Field of View (EFOV) of 85 cm is intended solely for use in treatment preparation and the planning\/simulation of radiation therapy. It cannot be used for diagnostic purposes. The water equivalent material external contour deviation of body system phantom positioned (partially) outside scan FOV with phantom edge adjacent to bore cover is within 1 mm in terms of mean Hausdorff distance compared to the true external contour.<\/p>\n\r\nFor further information, please contact:<\/b>\r\nJayme Maniatis\u00a0\r\nPhilips Global\u00a0External\u00a0Relations\u00a0\u00a0\r\nTel.:\u00a0+1 617 804 8368\r\nE-mail: jayme.maniatis@philips.com<\/a><\/pre>\n
About Royal Philips<\/h2>\n
Attachments<\/h2>\n
\n